The price-to-earnings ratio for Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) is 10.81x, which is above its average ratio. Moreover, the 36-month beta value for IRWD is 0.97. Analysts have varying opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The average price recommended by analysts for Ironwood Pharmaceuticals Inc. (IRWD) is $13.20, which is $2.32 above the current market price. The public float for IRWD is 150.89M and currently, short sellers hold a 10.72% of that float. On March 16, 2023, IRWD’s average trading volume was 1.98M shares.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
IRWD) stock’s latest price update
Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD)’s stock price has decreased by -2.71 compared to its previous closing price of 10.72. Despite this, the company has seen a fall of -2.89% in its stock price over the last five trading days.
IRWD’s Market Performance
Ironwood Pharmaceuticals Inc. (IRWD) has seen a -2.89% fall in stock performance for the week, with a -6.87% decline in the past month and a -14.01% plunge in the past quarter. The volatility ratio for the week is 2.54%, and the volatility levels for the past 30 days are at 2.73% for IRWD. The simple moving average for the last 20 days is -6.66% for IRWD stock, with a simple moving average of -8.28% for the last 200 days.
Analysts’ Opinion of IRWD
Many brokerage firms have already submitted their reports for IRWD stocks, with CapitalOne repeating the rating for IRWD by listing it as a “Overweight.” The predicted price for IRWD in the upcoming period, according to CapitalOne is $15 based on the research report published on September 02nd of the previous year 2022.
Piper Sandler, on the other hand, stated in their research note that they expect to see IRWD reach a price target of $16. The rating they have provided for IRWD stocks is “Overweight” according to the report published on April 22nd, 2022.
Wells Fargo gave a rating of “Equal Weight” to IRWD, setting the target price at $9 in the report published on September 30th of the previous year.
IRWD Trading at -8.52% from the 50-Day Moving Average
After a stumble in the market that brought IRWD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -19.46% of loss for the given period.
Volatility was left at 2.73%, however, over the last 30 days, the volatility rate increased by 2.54%, as shares sank -6.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.82% lower at present.
During the last 5 trading sessions, IRWD fell by -2.89%, which changed the moving average for the period of 200-days by -6.79% in comparison to the 20-day moving average, which settled at $11.14. In addition, Ironwood Pharmaceuticals Inc. saw -15.82% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IRWD starting from MCCOURT Thomas A, who sale 33,756 shares at the price of $11.22 back on Mar 03. After this action, MCCOURT Thomas A now owns 647,598 shares of Ironwood Pharmaceuticals Inc., valued at $378,742 using the latest closing price.
MCCOURT Thomas A, the Chief Executive Officer of Ironwood Pharmaceuticals Inc., sale 31,227 shares at $11.31 during a trade that took place back on Feb 28, which means that MCCOURT Thomas A is holding 681,354 shares at $353,177 based on the most recent closing price.
Stock Fundamentals for IRWD
Current profitability levels for the company are sitting at:
- +60.97 for the present operating margin
- +99.65 for the gross margin
The net margin for Ironwood Pharmaceuticals Inc. stands at +42.64. Equity return is now at value 30.50, with 16.70 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 30.58.
Conclusion
To wrap up, the performance of Ironwood Pharmaceuticals Inc. (IRWD) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
